ACIU PE Ratio & Valuation,Is ACIU Overvalued

ACIU Relative Valuation

ACIU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ACIU is overvalued; if below, it's undervalued.

Historical Valuation

AC Immune SA (ACIU) is now in the Fair zone, suggesting that its current forward PS ratio of 5.26 is considered Fairly compared with the five-year average of -6.58. The fair price of AC Immune SA (ACIU) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：3.15

Fair

0.00

EV/EBITDA

AC Immune SA. (ACIU) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -11.32. The thresholds are as follows: Strongly Undervalued below -75.07, Undervalued between -75.07 and -43.20, Fairly Valued between 20.55 and -43.20, Overvalued between 20.55 and 52.43, and Strongly Overvalued above 52.43. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.99

EV/EBIT

AC Immune SA. (ACIU) has a current EV/EBIT of -1.99. The 5-year average EV/EBIT is -2.63. The thresholds are as follows: Strongly Undervalued below -15.05, Undervalued between -15.05 and -8.84, Fairly Valued between 3.59 and -8.84, Overvalued between 3.59 and 9.80, and Strongly Overvalued above 9.80. The current Forward EV/EBIT of -1.99 falls within the Historic Trend Line -Fairly Valued range.

5.23

AC Immune SA. (ACIU) has a current PS of 5.23. The 5-year average PS is 46.08. The thresholds are as follows: Strongly Undervalued below -156.49, Undervalued between -156.49 and -55.20, Fairly Valued between 147.36 and -55.20, Overvalued between 147.36 and 248.64, and Strongly Overvalued above 248.64. The current Forward PS of 5.23 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

AC Immune SA. (ACIU) has a current P/OCF of 0.00. The 5-year average P/OCF is -12.66. The thresholds are as follows: Strongly Undervalued below -102.71, Undervalued between -102.71 and -57.69, Fairly Valued between 32.36 and -57.69, Overvalued between 32.36 and 77.39, and Strongly Overvalued above 77.39. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.17

P/FCF

AC Immune SA. (ACIU) has a current P/FCF of -3.17. The 5-year average P/FCF is -0.50. The thresholds are as follows: Strongly Undervalued below -33.17, Undervalued between -33.17 and -16.84, Fairly Valued between 15.83 and -16.84, Overvalued between 15.83 and 32.16, and Strongly Overvalued above 32.16. The current Forward P/FCF of -3.17 falls within the Historic Trend Line -Fairly Valued range.

AC Immune SA (ACIU) has a current Price-to-Book (P/B) ratio of 4.10. Compared to its 3-year average P/B ratio of 1.94 , the current P/B ratio is approximately 111.17% higher. Relative to its 5-year average P/B ratio of 1.86, the current P/B ratio is about 119.74% higher. AC Immune SA (ACIU) has a Forward Free Cash Flow (FCF) yield of approximately -19.13%. Compared to its 3-year average FCF yield of -12.36%, the current FCF yield is approximately 54.73% lower. Relative to its 5-year average FCF yield of -16.09% , the current FCF yield is about 18.92% lower.

4.45

P/B

Median3y

1.94

Median5y

1.86

-19.22

FCF Yield

Median3y

-12.36

Median5y

-16.09

Competitors Valuation Multiple

The average P/S ratio for ACIU's competitors is 2.03, providing a benchmark for relative valuation. AC Immune SA Corp (ACIU) exhibits a P/S ratio of 5.23, which is 157.39% above the industry average. Given its robust revenue growth of -96.32%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ACIU increased by 16.67% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.05 to -3.82.

The secondary factor is the Revenue Growth, contributed -96.32%to the performance.

Overall, the performance of ACIU in the past 1 year is driven by P/E Change. Which is more unsustainable.

-96.32%

25.49M → 939.00K

Revenue Growth

-7922.23%

21.59 → -1.69K

Margin Expansion

8035.22%

-0.05 → -3.82

P/E Change

16.67%

2.70 → 3.15

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is AC Immune SA (ACIU) currently overvalued or undervalued?

What is AC Immune SA (ACIU) fair value?

ACIU's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AC Immune SA (ACIU) is between to according to relative valuation methord.

How does ACIU's valuation metrics compare to the industry average?

What is the current P/B ratio for AC Immune SA (ACIU) as of Dec 15 2025?

As of Dec 15 2025, AC Immune SA (ACIU) has a P/B ratio of 4.10. This indicates that the market values ACIU at 4.10 times its book value.

What is the current FCF Yield for AC Immune SA (ACIU) as of Dec 15 2025?

As of Dec 15 2025, AC Immune SA (ACIU) has a FCF Yield of -19.13%. This means that for every dollar of AC Immune SA’s market capitalization, the company generates -19.13 cents in free cash flow.

What is the current Forward P/E ratio for AC Immune SA (ACIU) as of Dec 15 2025?

As of Dec 15 2025, AC Immune SA (ACIU) has a Forward P/E ratio of -5.91. This means the market is willing to pay $-5.91 for every dollar of AC Immune SA’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for AC Immune SA (ACIU) as of Dec 15 2025?

As of Dec 15 2025, AC Immune SA (ACIU) has a Forward P/S ratio of 5.26. This means the market is valuing ACIU at $5.26 for every dollar of expected revenue over the next 12 months.

ACIU Valuation